Novation’s semi-annual Drug Price Forecast is designed to offer information and support resources to aid in the development of annual drug budget projections. The report summary includes the following key points:
• Novation projects an estimated weighted drug price inflation of 1.36 percent through June 2013, driven by continued developed of generic alternatives to brand-name pharmaceuticals.
• Contract products will see a 0.24 percent price change, while non-contract pharmaceuticals will see a 2.66 percent price change.
• Antineoplastic agents, serums and hematopoietic agents are the top three therapeutic classes, making up 20.6 percent, 8.7 percent and 8.6 percent of aggregate acute purchases.
• Other top therapeutic classes include disease modifying anti-rheumatic agents, heparins, hemostatics and vaccines.
To view Novation’s Drug Price Forecast Summary Report, Winter 2012 in full, click here.
Related Articles on Supply Chain:
Provista Names Dino Eliopoulos CFO
Spencer Hospital, Surgery Center Approves $306k Lease With Stryker Endoscopy
AdvaMed’s President Issues Statement on ‘Ensuring Safe Medical Devices for Patients’ Legislation
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
